HomeREGULATORY
REGULATORY

Exempt Some LLPs from New G1/G2 Price Scheme for Off-Patent Drugs: FPMAJ
(Nov.30.2017)

FPMAJ Chairman Masayo Tada (left), JPMA President Yoshihiko Hatanaka
The Federation of Pharmaceutical Manufacturers’ Associations of Japan (FPMAJ) on November 29 called for excluding certain types of off-patent brand-name drugs from a new “G1/G2” pricing scheme proposed by the government that would gradually diminish their price differences with generics ...
(LOG IN FOR FULL STORY)